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Background: EBV DNA is found within the malignant cells of 10% of gastric cancers. Modern molecular technology
facilitates identification of virus-related biochemical effects that could assist in early diagnosis and disease
management.
Methods: In this study, RNA expression profiling was performed on 326 macrodissected paraffin-embedded tissues
including 204 cancers and, when available, adjacent non-malignant mucosa. Nanostring nCounter probes targeted
96 RNAs (20 viral, 73 human, and 3 spiked RNAs).
Results: In 182 tissues with adequate housekeeper RNAs, distinct profiles were found in infected versus uninfected
cancers, and in malignant versus adjacent benign mucosa. EBV-infected gastric cancers expressed nearly all of the
18 latent and lytic EBV RNAs in the test panel. Levels of EBER1 and EBER2 RNA were highest and were proportional
to the quantity of EBV genomes as measured by Q-PCR. Among protein coding EBV RNAs, EBNA1 from the Q
promoter and BRLF1 were highly expressed while EBNA2 levels were low positive in only 6/14 infected cancers.
Concomitant upregulation of cellular factors implies that virus is not an innocent bystander but rather is linked to
NFKB signaling (FCER2, TRAF1) and immune response (TNFSF9, CXCL11, IFITM1, FCRL3, MS4A1 and PLUNC), with PPARG
expression implicating altered cellular metabolism. Compared to adjacent non-malignant mucosa, gastric cancers
consistently expressed INHBA, SPP1, THY1, SERPINH1, CXCL1, FSCN1, PTGS2 (COX2), BBC3, ICAM1, TNFSF9, SULF1,
SLC2A1, TYMS, three collagens, the cell proliferation markers MYC and PCNA, and EBV BLLF1 while they lacked CDH1
(E-cadherin), CLDN18, PTEN, SDC1 (CD138), GAST (gastrin) and its downstream effector CHGA (chromogranin).
Compared to lymphoepithelioma-like carcinoma of the uterine cervix, gastric cancers expressed CLDN18, EPCAM,
REG4, BBC3, OLFM4, PPARG, and CDH17 while they had diminished levels of IFITM1 and HIF1A. The druggable targets
ERBB2 (Her2), MET, and the HIF pathway, as well as several other potential pharmacogenetic indicators (including
EBV infection itself, as well as SPARC, TYMS, FCGR2B and REG4) were identified in some tumor specimens.
Conclusion: This study shows how modern molecular technology applied to archival fixed tissues yields novel
insights into viral oncogenesis that could be useful in managing affected patients.
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Gastric cancer is the second leading cause of global can-
cer mortality with nearly one million new cases per year
[1,2]. Approximately ten percent of gastric adenocarcin-
omas are Epstein-Barr virus (EBV) infected, and EBV is
considered a class 1 oncogenic pathogen by the World
Health Organization [3-6]. Incidence is rising for those
cancers in the proximal segment of the stomach (cardia,
corpus) where EBV is more frequently involved [7-14].
Recent data from the National Cancer Institute’s cancer
surveillance program shows a worrisome rise in gastric
cancer incidence among young adults in the US [7,8,15].
Emerging targeted therapy makes it all the more import-
ant to identify infected cancers and to characterize bio-
chemical defects such as ERBB2 overexpression that
increases likelihood of response to trastuzumab in meta-
static gastric cancer patients [16-18]. EBV-infected com-
pared to uninfected gastric cancer has a favorable
prognosis [19], and clinical trials are beginning to explore
virus-targeted therapy such as 1) infused EBV-specific
cytotoxic T cells or NK cells [20-23], 2) reversing the
EBV-related methylator phenotype [24], 3) triggering
lytic viral replication that could then incite the body’s in-
nate and adaptive immune responses to kill infected
tumor cells [25-33], and 4) lytic induction therapy co-
administered with antiviral nucleoside analog such as
gancyclovir that is phosphorylated and thus activated by
viral kinases promoting cytotoxicity [34-41].
Clinical trials examining the efficacy of targeted therapy
would benefit from laboratory assays that help identify
candidates likely to respond, and could benefit from la-
boratory assays that signify the effect of intervention on
the intended biochemical pathways. Modern molecular
technology now permits clinical-grade analysis of multiple
pertinent analytes via RNA expression profiling [42]. De-
vice manufacturers have produced sensitive, specific and
customizable probe arrays to simultaneously measure
multiple RNAs, including non-coding RNAs like EBV-
encoded RNA 1 or 2 that are abundantly expressed in
infected tumors. Recent progress in quality assurance
strategies have matured to the point that RNA expression
profiles are being implemented in clinical laboratory set-
tings [42].
To be practical in clinical settings, an assay must be
applicable to routinely collected specimens such as arch-
ival, paraffin-embedded tissue [42]. In the current study,
we measured viral and human gene expression in arch-
ival gastric cancers and in adjacent mucosa and controls
to develop a test systems that might be used to reliably
characterize signatures predictive of response to targeted
therapy. A 96-RNA array test system that we dub the
Gastrogenus v1™ panel was customized to measure per-
tinent latent and lytic viral RNAs alongside clinically
relevant human mRNAs that were previously reportedto be 1) gastric cancer specific, 2) indicative of inflam-
mation, and/or 3) predictive of response to specific med-
ications. These assays, as well as spiked and endogenous
control RNAs, were measured in macrodissected paraf-
fin sections using the Nanostring nCounter test system
[43-45]. Correlative histologic and molecular studies
were done to demonstrate that the test system per-
formed as expected. Our findings show that EBV-related
cancers express more latent and lytic transcripts than
were previously recognized, and that infected cancers
have unique biologic characteristics compared with un-
infected cancers. Two major subtypes of cancer were
found, implying that gastric cancer early detection strat-
egies or monitoring tests could be tailored to detect the
pertinent signatures characterizing major molecular sub-
types. Finally, pilot data reveals expression of selected
viral and cancer-related genes in adjacent non-malignant
mucosa, suggesting a field effect that could be important
in cancer development or maintenance.Results
Gene expression profiling was performed on a total of
326 tissues including 187 gastric cancers, 17 lymphoe-
pithelioma-like cervical cancers, and 118 matched non-
malignant mucosa from the same surgical procedure
(when available). After data normalization, a heat map of
the 182 tissues having the best quality RNA, as judged by
highest average level of four housekeeping RNAs,
revealed patterns of gene expression that differed in gas-
tric versus cervical control tissues. Furthermore, in both
the gastric and cervical clusters, malignant and non-
malignant tissues tended to cluster together, supporting
the ability of the nCounter test system to measure clinic-
ally important biologic features. (See Figure 1.)
One group of gastric carcinomas overexpressed virtu-
ally all of the EBV RNAs. To determine which gastric
cancers should be designated as EBV-infected, the 71 tis-
sues with the highest combined levels of EBER1 and
EBER2 RNA by Nanostring nCounter array were further
examined for EBV genome levels within the same tissue
by Q-PCR. There was a linear relationship between the
amount of EBER1 and EBER2 RNA and the amount of
EBV genome. (See Figure 2.) Our previously established
cutoff [46] for the level of EBV genome corresponding
to localization of virus to malignant cells resulted in 14
cancers being placed in the EBV-infected category. The
remaining gastric cancers were called EBV-negative, and
among them the highest recorded RNA levels were
174,016 for EBER1 and 27,972 for EBER2. In contrast,
among the EBV-infected gastric cancers the lowest
EBER1 level was 263,589 and the lowest EBER2 level
was 140,081. Proposed cutoffs for identifying a tissue as
EBV-infected are shown in Figure 2.
Figure 1 Expression profiles of 182 tissues for 20 viral genes and 73 human genes. A heat map displays unsupervised hierarchical
clustering of each tissue in a separate column, and each RNA in a separate row. The data is median-centered with red indicating relative
overexpression and green indicating relative under-expression for each gene. Correlative data above the map indicates histopathologic
classification with further subclassification of the gastric cancer cohort into 14 EBV infected and 104 EBV negative cancers based on EBV DNA
levels. Below the map, each gastric cancer is categorized by the proportion of malignant cells, and geographic origin of each tissue is shown.
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gastric cancer
Twenty eight genes were significantly differentially
expressed in EBV-infected cancers compared to the EBV
negative gastric cancers (p < 0.05). Interestingly, all 28
were upregulated rather than downregulated in the
infected cancers, and this bias is explained at least in part
by our selection of positive rather than negative markers
of infection when choosing the RNAs to be profiled for
this study. Failure to identify any downregulated genes
was still surprising given reports that EBV is associated
with a CpG island methylator phenotype and additionally
the virus can destabilize cellular mRNAs globally [47].
Among the genes significantly upregulated in infected
cancers were all 18 of the EBV RNAs tested, as well as
cytomegalovirus pp65 (UL83). The cytomegalovirus
pp65 (UL83) result is likely to be false positive (sus-
pected to be probe cross hybridization), as evidenced by
absence of another lytic RNA, cytomegalovirus pol
(UL54), in the EBV-infected cancers. Furthermore, UL83
but not UL54 was expressed in EBV infected but not in
EBV-negative cell line controls (data not shown).Another possible explanation for false positive viral RNA
expression is probe crossreactivity with viral DNA. Nine
human RNAs were significantly upregulated in EBV-
infected compared to EBV negative gastric cancers:
FCER2, MS4A1 (CD20), PLUNC, TNFSF9, TRAF1,
CXCL11, IFITM1, PPARG, and FCRL3. (See Figure 3).
Genes differentially expressed in gastric cancer compared
to non-malignant gastrointestinal mucosa
Twenty six genes were significantly dysregulated in gastric
cancer compared to non-malignant gastric mucosa
(p < 0.05). The human RNAs upregulated in gastric cancer
were INHBA, SPP1, THY1, SERPINH1, CXCL1, FSCN1,
COL1A1, SPARC, COL1A2, PTGS2 (COX2), BBC3,
ICAM1, TNFSF9, MYC, SULF1, SLC2A1, COL3A1, PCNA,
and TYMS, while the downregulated RNAs were CDH1
(E-cadherin), CLDN18, CHGA (chromogranin), PTEN,
SDC1 (CD138) and GAST (gastrin). The only viral factor
that was differentially expressed was BLLF1 which
was significantly higher in cancer than in non-
malignant gastric mucosa (p = 0.004). BLLF1 encodes
the late viral envelope protein gp350/220, suggesting
Figure 2 EBV-encoded RNA levels are high in infected gastric cancer and are proportion to EBV genome level. A. Box plots of EBER1 and
EBER2 in benign and malignant tissues reveal that EBV-infected gastric cancer has substantially higher levels of EBER1 and EBER2 non-coding RNAs
than do uninfected cancers and control tissues. Proposed thresholds for EBER1 or EBER2 are shown beyond which a gastric cancer could reliably
be designated as EBV-infected. Each dot represents an individual analytic result on a log2 normalized unit (NU) scale. B. Pairwise comparison of
EBER1 and EBER2 RNA levels by Nanostring nCounter array and EBV DNA viral load by Q-PCR reveals a linear association between levels of each of
these analytes. Pearson correlation coefficients (P >0.86) are shown. The previously validated level of EBV DNA viral load is shown beyond which
EBER was always localized to malignant cells by EBER in situ hybridization (threshold of 10,558 EBV genomes per 100,000 cells, which is equivalent
to 13.37 on this log2 scale) [46]. Proposed cutoffs for RNA levels are indicated for both EBER1 (200,000 NU, or 17.61 on this log 2 scale) and EBER2
(100,000 NU, or 16.61 on this log2 scale). The one outlier is a non-malignant gastric mucosa that was located adjacent to an EBV-infected gastric
cancer, and this mucosa had an EBV DNA load equivalent to that of infected cancers, but it would have been correctly excluded from the EBV-
infected cancer group if either EBER1 or EBER2 RNA levels were used, or if histology were used, to screen for EBV-related malignancy.
Tang et al. Infectious Agents and Cancer 2012, 7:21 Page 4 of 15
http://www.infectagentscancer.com/content/7/1/21that virions are significantly more prevalent in cancer
than in non-malignant gastric tissue. BLLF1 was not
specific for gastric cancer, however, as it was also
expressed in some benign and malignant cervical tis-
sues, as well.Genes associated with gastric cancer compared to
lymphoepithelioma-like cervical cancer
Nine genes were significantly dysregulated in gastric
cancer compared to lymphoepithelioma-like cervical
cancer (p < 0.05). The seven RNAs upregulated in gastric
cancer were CLDN18, EPCAM, REG4, BBC3, OLFM4,
PPARG, and CDH17, while the two downregulated genes
were IFITM1 and HIF1A.Patterns of latent and lytic viral gene expression in EBV
infected gastric cancers
The 14 EBV-infected gastric cancers in this study con-
sistently coexpressed virtually all of the EBV latent and
lytic genes, which is somewhat surprising given that
prior literature describes a somewhat restricted latency
pattern [48-51]. It is feasible that the Nanostring nCoun-
ter analytic technology is more sensitive than traditional
methods of detection.
The most highly expressed viral RNA was EBER1 at an
average of over 1 million normalized units per EBV-
infected cancer tissue, followed by EBER2, BRLF1 and
EBNA1 from of the Q promoter. EBNA2 was the least
expressed viral RNA with a mean expression of only 10
normalized units per infected tissue and EBNA2 was
Figure 3 Multiple human RNAs are over-expressed in EBV-infected gastric cancer compared to EBV-negative cancer. Box plots
demonstrate the human RNAs levels in infected compared to uninfected gastric cancers and controls that include lymphoepithelioma-like
cervical cancer, cervical mucosa, and benign gastrointestinal mucosa. Each dot represents an individual analytic result on a log2 normalized unit
scale.
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Patterns of viral gene expression are depicted in
Figure 4.
Geographic origin and tumor cell proportion are not
preferentially associated with EBV status of gastric cancer
Below the heat map in Figure 1 is the distribution of
gastric cancer cases by geographic origin from Honduras
(n = 86), Japan (n = 5), or the United States (n = 17).
There was no significant association between geographic
origin and EBV-positive versus negative clustering of
gastric cancers (Fisher’s exact test p = 0.9), suggesting
that geographic origin is not the major driver of hier-
archical clustering.
The bottom of Figure 1 also shows the distribution of
EBV-infected versus EBV-negative gastric cancers classi-
fied by the proportion of malignant cells input into the ex-
pression profiling assay. There was no significant
association between the proportion of malignant cells and
the EBV-infected versus EBV-negative groups of gastric
cancer. Surprisingly, the cancer tissues with low malignant
cell content did not preferentially cluster with the non-
malignant gastric tissues. Cancers with low malignant cell
content (1 to 25% malignant cells) were distributed acrossvarious segments of the heat map along with cancers with
medium (26 to 50%) or high (>50%) malignant cell con-
tent (Fisher’s exact test p = 0.5), suggesting that overall
transcriptome features outweigh tumor cell proportion as
the driver of hierarchical clustering.
Keeping in mind that the lymphoepithelioma-like cer-
vical cancers in this study were rich in lymphoid stroma,
as are many EBV-infected gastric cancers, it is remark-
able that these two classes of cancer clustered separately
from each other and also achieved reasonably good sep-
aration from adjacent non-malignant mucosa. For most
genes in the panel, there is considerable overlap in levels
across disease types. While profiles are more informative
and more convincing than are individual transcript
results, there is some overlap in profiles as well, signify-
ing that profiling assay results must be correlated with
histologic features in order to accurately classify a tissue
as benign or malignant.
Pharmacogenetic predictors and druggable targets
EBV infection itself is considered an actionable target, at
least for the 14/108 (13%) infected gastric cancers we
identified. This study demonstrates a novel way to iden-
tify virus-infected cancers by RNA profiling of paraffin
Figure 4 Latent and lytic EBV genes are co-expressed in gastric cancer. A portion of the heat map from Figure 1 is displayed in high
contrast to decipher relative expression levels of EBV genes in the 14 EBV-infected gastric cancers and surrounding specimens. All tissues are
gastric cancers except a single non-malignant gastric mucosa, shown in grey, dissected from the same paraffin block as an EBV-infected gastric
cancer. Mean expression level of each RNA in the EBV-infected gastric cancer cohort is shown to the right of each gene symbol.
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may be considered in patient management decisions.
Cellular factors of pharmacogenetic potential include the
HIF pathway, SPARC, TYMS, FCGR2B, MET, and
ERBB2 (Her2). (See Figure 5). Compared with gastric
cancers, cervical cancers tend to have higher levels of
HIF1A indicating hypoxia response, although equally
high levels in non-malignant cervical mucosa raise the
possibility of ex vivo stimulation of this oxygen-sensing
factor. Further study is needed to distinguish technical
factors from in vivo upregulation that would warrant
consideration of angiogenesis inhibitors.
We confirmed that SPARC is upregulated in gastric
cancer compared to benign gastric mucosa. Response to
docetaxel, a taxane drug that inhibits mitotic spindle as-
sembly, is reportedly impacted by the amount of SPARC
protein expression in gastric cancer [52]. Gastric and
cervical cancers both had higher thymydylate synthase
(TYMS) than did their respective benign mucosal coun-
terparts. High TYMS levels reportedly contributes to
acquired resistance to 5FU combination therapy [53].
A few gastric cancers had extremely high levels of the Fc
receptor, FCGR2B, which could affect drug internalization
and pharmacodynamics of therapeutic antibodies such ascetuximab in vivo. Four gastric cancers strongly expressed
MET, and an additional eight cases strongly overexpressed
expressed ERBB2 (Her2), raising the possibility that this
assay could predict response to tyrosine kinase inhibitor
therapy.
Discussion
This study used modern molecular methods to examine
a large panel human and viral RNAs in gastric cancer.
To our knowledge, this is the largest panel of viral gene
products to be examined in concert with human RNAs
in archival, paraffin embedded tissues. The EBV-infected
subtype of gastric cancer is dramatically evident in the
corresponding heat map created by unsupervised clus-
tering, and EBV infection was confirmed by high EBV
DNA viral loads in these tissues. Expression of selected
viral and human genes in the cancers confirmed several
known virus- and cancer-related effects and also
revealed novel findings that shed light on pathogenesis
and possible disease management strategies.
Surprisingly, the infected gastric cancers overexpressed
all 18 of the latent and lytic EBV genes that were tested.
We discovered high levels of BRLF1 RNA (encoding the
immediate early viral protein triggering lytic replication
Figure 5 Some gastric cancers have significant dysregulation of factors that show promise as pharmacogenetic predictors. Box plots
demonstrate expression of selected pharmacogenetic targets in infected versus non-infected gastric cancers as well as non-malignant gastric
mucosa and cervical histopathologies. Each dot represents an individual analytic result on a log2 normalized unit scale.
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BXLF1 (the viral thymidine kinase that converts penicy-
clovir to a toxic form, suggesting a mechanism for ther-
apy) [54]. BLLF1 (encoding the late viral envelope
protein gp350/220) was expressed at moderate levels
that were nevertheless significantly higher than in non-
malignant mucosa, suggesting that EBV lytic infection is
not abortive but rather is capable of producing the late
viral envelope protein gp350/220. Among the latent
genes, EBNA1 from the Q promoter, EBNA-LP, and
EBNA3C transcripts were most prevalent. EBNA2 was
focally detected at low level but was still significantly
higher in infected than in uninfected gastric cancers.
Prior histochemical work has generally not revealed
protein-level expression of the EBNAs or lytic viral gene
products, so further work is required to learn if these
virally encoding RNAs are localized to malignant cells,
lymphocytes, or possibly even to exosomes or virions in
the extracellular milieu.
Compared to uninfected cancers, the infected cancers
had significant upregulation of nine cellular factors
(FCER2, MS4A1 (CD20), PLUNC, TNFSF9, TRAF1,
CXCL11, IFITM1, PPARG, and FCRL3), implying that
EBV is not an innocent bystander with respect to bio-
chemical impact. The virus-associated changes we found
were in pathways known to viral oncologists, namely
NFKB and NOTCH signaling (FCER2, TRAF1, PPARG)
and mucosal immune response (PLUNC, TNFSF9,
CXCL11, IFITM1, FCRL3). MS4A1 (CD20) is B cell spe-
cific, reminding us that some of the factors upregulated inEBV-infected compared to uninfected gastric cancers
could derive from stromal elements rather than from ma-
lignant epithelial cells. PLUNC was previously described as
a tumor marker for gastric and nasopharyngeal carcin-
omas, and it encodes a secreted protein involved in innate
immune response [55-57]. TNFSF9, a cytokine of the
tumor necrosis factor family, stimulates T cell activation
and triggers IFNG production which in turn induces the
proinflammatory chemokine CXCL11 and the innate anti-
viral factor IFITM1. PPARG is as a nuclear receptor con-
trolling glucose metabolism and microtubule networks,
and it is a promising target for inhibitory drugs [58]. The
FCRL3 immune response gene is mutated in autoimmune
diseases such as rheumatoid arthritis, lupus, and Grave’s
disease.
Our findings support the work of Lee et al who found
distinct human expression patterns in infected versus
uninfected gastric cancers [10]. Although their study tar-
geted protein and ours targeted RNA, our findings
agreed with theirs for 4 of the 5 factors in common be-
tween the two studies (BCL2, PTEN, CDH1, PTGS2).
There was a potential discrepancy for ERBB2 that was
significantly less frequently expressed in infected com-
pared to uninfected gastric cancers when tested at the
protein level [10], whereas the current study showed no
significant difference at the RNA transcript level. Con-
founding factors include 1) the proportion of tumor cells
present in the specimens evaluated, 2) different criteria
for categorizing expression status, and 3) RNA versus
protein targets.
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study worked remarkably well in generating RNA pro-
files that were believable by virtue of distinguishing
known benign versus malignant and gastric versus cer-
vical histopathologies. Furthermore, co-expression of
analytes in the same pathway or by the same infectious
agent makes sense from a pathobiology and virology per-
spective. Interestingly, all of the cervical tissues clustered
together, and benign and malignant cervical lesions were
largely segregated even though the Gastrogenus v1™ test
panel had not been specifically designed to achieve these
endpoints. Lack of multiple co-expressed EBV mRNAs
in cervical tissues reinforced what we knew about their
EBV-negativity by the gold standard EBER in situ
hybridization assay.
Among the seven genes that were significantly more
expressed in gastric cancer (regardless of infection sta-
tus) compared to lymphoepithelioma-like cervical can-
cer, four were previously reported as gastric cancer
markers (CLDN18, REG4, OLFM4, CDH17) [55,59-63].
Two others (EPCAM epithelial cell specific trans-
membrane glycoprotein, and PPARG chemokine), as
well as REG4, are being explored for targeted cancer
therapy [64-66]. The last of the seven, BBC3 (also called
p53 up-regulated modulator of apoptosis, or PUMA) is
reportedly upregulated by EBV LMP2A and reigned in
by EBV miR-BART5 in cell line models [67,68], suggest-
ing that this BCL2 family member is tightly regulated by
the virus.
One of the two RNAs that was significantly higher in
cervical compared to gastric cancer was IFITM1, which
you may recall was also found to be overexpressed in
infected compared to uninfected gastric cancers. Further
work is needed to explore if cervical cancers (presum-
ably human papillomavirus-infected) and EBV-infected
gastric cancers share a common virus-related mechan-
ism for overexpression of this innate immune response
factor. The other gene significantly overexpressed in cer-
vical compared with gastric cancer was HIF1A whose ex-
pression was associated with that of four downstream
angiogenesis mediators in our panel (VEGFA, SLC2A1,
SLC2A3 and EPAS1) as evidenced by positive Pearson’s
correlation coefficients (data not shown). If confirmed to
be operative in vivo, HIF pathway stimulation implies
that angiogenesis inhibitors are worth investigating.
Benign versus malignant gastric tissues tend to cluster
separately on the heat map, with some exceptions. Field
effect [69] or exosomal transfer of factors to adjacent
regions of the local environment [70,71] could explain
why some cancers and adjacent reactive tissues had
similar profiles. While macrodissection was used to care-
fully separate benign from malignant lesions, we cannot
exclude occult malignancy as a contributor to aberrant
clustering.Among the 19 genes significantly upregulated in gas-
tric cancer compared to adjacent non-malignant gastric
mucosa, most were previously reported as gastric cancer
specific markers [72-76], and we now confirm that their
upregulation is detectable in archival paraffin-embedded
tissue. Lower levels of GAST (gastrin) RNA in cancer tis-
sues could help explain the concomitant loss of the gas-
trin signaling factor CHGA (chromogranin). The most
consistently downregulated factor in gastric cancer ver-
sus adjacent benign mucosa was the tumor suppressor
gene CDH1 (E-cadherin) suggesting either 1) CDH1 pro-
moter hypermethylation [77], 2) rare germline mutation
of CDH1 associated with heritable predisposition to gas-
tric cancer [78], or 3) downregulation of CDH1 by EBV
LMP1 as described in cell line models [79].
LMP1 was previously reported to be absent in infected
gastric cancer except in rare cases [50,51,80,81]. It was
therefore surprising that Nanostring nCounter array pro-
filing showed consistent albeit low level expression of
LMP1 RNA along with virtually all of the other EBV
RNAs that were tested in the infected gastric cancers.
Coordinated co-expression of multiple viral genes argues
that the expression is true positive. Our microarray
results raise the possibility that the viral RNAs we
detected are not encoding proteins or that the proteins
are 1) only transiently expressed, 2) rapidly degraded, 3)
localized to rare cells that are promptly recognized and
destroyed by the immune system, or 4) present at such
low level that traditional assays are too insensitive to de-
tect them [82]. The nCounter test system manufacturer
claims analytic sensitivity equivalent to that of rtPCR
[43].
While most viral genes were expressed almost exclu-
sively in the infected gastric cancer cohort, EBER1 and
EBER2 were commonly expressed in each one of the be-
nign and malignant gastric and cervical cohorts, albeit at
much lower levels than was seen in each of the EBV-
infected gastric cancers. Indeed, our study revealed a
novel way to identify EBV-infected gastric cancer by
measuring EBER1 and/or EBER2 RNA in archival tissue,
and we have proposed thresholds that successfully dis-
tinguish infected from uninfected gastric cancer.
Support for active viral infection in infected gastric
cancer patients comes from serologic evidence of higher
titers against viral capsid antigen compared to EBV-
negative gastric cancer patients and benign controls
[83]. Low level lytic infection was previously described
in mucosal lymphoid cells [31,82,84] and in infected gas-
tric epithelial cell lines [85]. BARF1 is known to be
expressed in gastric cancer where it is proposed to act as
a latent rather than a lytic factor [50,51]. Using sensitive
rtPCR technology, multiple EBV lytic transcripts were
detected by Luo et al in gastric cancer tissues [50].
Whether active replicative infection occurs in malignant
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since histochemical stains have failed to reveal a cellular
source of lytic factors in gastric tissues [82].
While EBV-infected gastric cancer is biologically distinct
from EBV-negative cancer in some respects, the infected
counterparts still share many of the classic features previ-
ously identified as being characteristic of gastric cancer,
such as specific collagens (COL1A1, COL1A2, COL3A1),
SULF1, THY1, SPP1, INHBA, and SPARC [76]. These pan-
gastric cancer markers might be exploited for early diag-
nosis or for monitoring tumor burden during therapy, es-
pecially when multiple such markers are tested in concert
to maximize specificity while still capturing the heterogen-
eity of the disease. Biomarkers for the EBV-infected sub-
set, such as EBV DNA and the highly expressed viral
EBER1, EBER2, EBNA1, and BRLF1 RNAs, as well as asso-
ciated cellular factors confirmed in this study, represent
promising targets for early detection. To the extent that
any of these factors circulate in blood, they might serve as
non-invasive indicators of disease analogous to what has
already been achieved for two other EBV-infected
neoplasms-- post transplant lymphoproliferative disorder
and nasopharyngeal carcinoma. In both of these disorders,
Q-PCR of circulating EBV DNA facilitates early diagnosis
and in monitoring efficacy of therapy [86-88]. High levels
of EBER1 and EBER2 RNA were measurable in plasma of
89% of nasopharyngeal carcinoma patients [89].
Antiviral therapy is becoming more accepted given its
biologic underpinnings-- the viral genome is present in
every malignant cell of a given infected cancer-- thus
making the virus one of the most appealing therapeutic
targets in our armamentarium. Off-the-shelf cytotoxic T
cells are now available to treat selected EBV-related ma-
lignancies [90,91]. Early clinical trial data demonstrate
the merits of lytic induction therapy [33,92,93]. Assess-
ment of lytic induction by panels of tests such as the
microarray system described herein could be useful for
measuring the biochemical impact of an intervention
and its efficacy.
Applicability of the Nanostring nCounter system to
archival paraffin embedded tissue was previously
reported by others [43,44], but ours is the first study to
examine viral and human RNAs in concert. The test sys-
tem’s ability to rapidly profile multiple RNAs generates
rich data relevant to viral oncology and patient care. A
major advantage is suitability for routine fixed tissue
specimens including small biopsies that were previously
collected, processed and stored using customary clinical
methods. While microscopy is essential to assuring that
representative tissue is input into the assay, the note-
worthy flexibility of the test system with regard to malig-
nant cell proportion promotes it use in clinical settings.
Panels of analytes could be tailored to support different
intended uses such as suitability of a subject for aspecific clinical trial, or monitoring efficacy of a given
regimen in serial specimens.
Conclusions
This study demonstrates the promise of array technology
to understand associations between viral and cellular
factors in naturally infected gastric cancers. We showed
major biologic differences between infected and unin-
fected cancers, between benign and malignant tissues,
and between gastric and cervical cancers. While prior
work indicates that the virus lies latent in malignant tis-
sue, we found evidence of active lytic infection and
virus-associated cellular changes that should be further
explored. Large panels of complementary tests promote
confidence in the findings and pave the way for design
of practical panels to be applied in clinical trials and,
once validated as useful, implemented in routine patient
care.
Materials and methods
Patient tissue and macrodissection
Formalin-fixed, paraffin-embedded gastric adenocarcinoma
tissues from the clinical archives of three hospitals in dis-
parate parts of the world were assembled, including 30
from the University of North Carolina Hospitals in Chapel
Hill, USA, 133 from Western Regional Hospital in Santa de
Rosa, Honduras, and 24 from Wakayama Medical Univer-
sity, Wakayama, Japan. As a control, 16 paraffin embedded
tissues diagnosed as lymphoepithelioma-like carcinoma of
the uterine cervix were retrieved from the archives of the
University of North Carolina Hospitals in Chapel Hill. All
studies were done with approval of our Institutional Review
Board, University of North Carolina Biomedical IRB.
On each paraffin block, nine formalin-fixed, paraffin-
embedded tissue sections, each 5uM thick, were cut. One
section was stained with hematoxylin and eosin so that a
pathologist could mark areas containing at least 50% ma-
lignant cells among all cells present. Cancers with less
tumor were still included in the study after further cat-
egorizing them as having either 1 to 25% or 25 to 50% ma-
lignant cells in marked areas of the slide. A scalpel was
used to scrape and combine the marked malignant cell-
rich areas from 8 unstained sections. When non-
malignant mucosa from the same surgical procedure was
available, the non-malignant tissue was macrodissected
from unstained sections and separately prepared for ex-
pression profiling.
Nucleic acid isolation and expression profiling
Total nucleic acid was extracted using the HighPure
miR Isolation kit using the manufacturer's instructions
(Roche Applied Science). Nucleic acid quality and purity
were assessed by Nanodrop spectrophotometry, and a
500 ng aliquot was spiked with each of three exogenous
Table 1 RNAs targeted in the GastroGenus v1™ panel
Gene symbol Alternate symbol Function or utility Reference sequence or GeneID
Gastric cancer specific RNAs and gastrin signalling factors
REG4 Cell regeneration and growth NM_032044.3
OLFM4 Tumor growth & cell adhesion, olfactomedin NM_006418.3
DKK4 Embryonic development NM_014420.2
ODAM APin Enamel mineralization NM_017855
CSAG2 Drug resistance NM_001080848.2
MIA Growth inhibition NM_006533.2
CYP2W1 Drug metabolism, cytochrome p450 NM_017781.2
HORMAD1 Cell cycle regulation NM_032132.3
MMP10 Matrix metallopeptidase, remodeling NM_002425.2
FUS mRNA/miRNA processing NM_004960
CLDN18 Tight junction component, claudin NM_001002026
SERPINH1 Collagen synthesis, peptidase inhibitor, heat shock NM_004353
THY1 Control of inflammatory cell recruitment NM_006288
INHBA Inhibin, inhibits hormone secretion and cell growth NM_002192
CXCL1 Immune development and homeostasis, chemokine NM_001511
SPARC osteonectin Protects from apoptosis, docetaxel response NM_003118
SPP1 Osteogenesis, secreted phosphoprotein NM_000582
SULF1 Cell signaling, sulfatase NM_015170
COL1A1 Type I collagen component NM_000088
COL1A2 Type I collagen component NM_000089
COL3A1 Type III collagen component NM_000090
CDH1 E-Cadherin Cell adhesion, mutated in heritable gastric cancer NM_004360
EPCAM Epithelial cell adhesion NM_002354
GAST Stimulates stomach acid secretion NM_000805
CDH17 Peptide transporter, gastrin signalling NM_004063.3
CHGA Neuroendocrine cell, gastrin signalling NM_001275
PTGS2 COX2 Prostaglandin synthesis, gastrin signaling, druggable NM_000963.1
MYC Cell cycle regulator, gastrin signalling NM_002467.3
CCND1 BCL1 cell cycle regulator, gastrin signalling NM_053056.2
EBV-related inflammatory response genes and NFKB signaling factors
PLUNC Gastric and nasopharyngeal carcinoma NM_130852.2
MET Receptor tyrosine kinase, ongogene, drug target NM_000245.2
BACH1 Transcription factor NM_206866
BBC3 PUMA p53 target, pro-apoptotic target of EBV mir-BART5 NM_014417
CXCL11 Leukocyte trafficking, target of EBV mir-BHRF1-3 NM_005409
CDKN1A P21, WAF1 Cyclin-dependent kinase inhibitor, EBV miR target NM_000389.2
FCRL3 Immune regulation, Fc receptor-like tyrosine kinase NM_052939
CD70 T and NK cell activation, TNF ligand NM_001252
FSCN1 Cell morphology and motility NM_003088
TNFSF9 Antigen (Ag) processing, TNF ligand cytokine NM_003811
BCL2L11 BIM Activator of apoptosis, BCL2-like NM_006538
PTEN Tumor suppressor, EBV miR target NM_000314.3
PCNA DNA replication and repair, cell proliferation indicator NM_182649.1
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Table 1 RNAs targeted in the GastroGenus v1™ panel (Continued)
GPR183 G protein-coupled receptor, EBV-induced NM_004951
MX1 Mediates antiviral response, interferon response NM_001144925
IFITM1 Innate antiviral and interferon response NM_003641
FCGR2B Phagocytosis & antibody production NM_004001
ICAM1 NFKB regulated, cell adhesion NM_000201.2
TRAF1 NFKB regulated, TNF receptor NM_005658.3
FCER2 CD23 NFKB-regulated B cell differentiation, IgE receptor NM_002002.4
IL10 Anti-inflammatory cytokine regulates NFKB signalling NM_000572.2
Hematopoietic cell markers
PTPRC CD45 Pan-hematopoietic cell marker, T & B cell signaling NM_002838
MS4A1 CD20 B cell marker, differentiation NM_021950
IGLL1 CD179B B cell marker, growth NM_020070
BANK1 B-cell marker, receptor-induced calcium mobilization NM_017935
FAM129C B cell marker NM_173544
MUM1 IRF4 Late stage B cell, signaling & differentiation NM_032853
SDC1 CD138 Plasma cell, also epithelial cell binding and signaling NM_001006946
CD4 Helper T cells, MHC class II antigen processing NM_000616.3
CD8A Suppressor T cells, MHC class I antigen processing NM_001768
CD3G – Pan T cell marker, intracellular signaling NM_000073
GPR56 NK cell marker in peripheral tissues NG_011643.1
Pharmacogenetic factors impacting drug response
ERBB2 HER2 Kinase-mediated signaling, trastuzumab target NM_004448.2
PPARG Glucose and lipid metabolism NM_138711.3
TYMS Thymidylate synthase, DNA repair, 5FU response NM_001071.2
HIF1A Systemic response to hypoxia NM_001530.2
EPAS1 Angiogenesis NM_001430
VEGFA Mitogen for endothelial cells NM_001025366
SLC2A3 GLUT3 Glucose transporter NM_006931.2
SLC2A1 GLUT1 Glucose transporter NM_006516.2
Epstein-Barr virus (EBV) RNAs: NC_007605.1
LMP1 BNLF1 TNF/CD40 signalling, latent phase 3783750
LMP2A Cell survival , latent phase 3783751
EBNA1 BKRF1 Viral persistence, episome, latent phase 3783709
EBNA1,QUK Q promoter variant, viral persistence, latent phase 3783774
EBNA2 BYRF1 Transactivator, latent phase 3783761
EBNA3A BERF1 Immortalization, latent phase 3783762
EBNA-LP Transactivator, latent phase 3783746
EBER1 Non-coding RNA inhibits apoptosis, latent phase AJ507799.2 - 6629..6795
EBER2 Non-coding RNA inhibits apoptosis, latent phase AJ507799.2 - 6956..7128
BZLF1 Zta, Zebra Immediate early transactivator of lytic replication 3783744
BMRF1 Early lytic DNA polymerase processivity factor, TF 3783718
BHRF1 Viral BCL2 inhibits apoptosis, early lytic phase 3783706
BCRF1 Viral interleukin 10 homologue 3783689
BARF1 Soluble CSF1 receptor homologue, early lytic phase 3783772
BRLF1 Rta Immediate early transactivator of lytic replication 3783727
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Table 1 RNAs targeted in the GastroGenus v1™ panel (Continued)
BLLF1 gp350/220 Viral entry via CD21 receptor, late lytic phase 3783713
BALF5 Viral DNA polymerase, early lytic phase 3783681
BXLF1 Thymidine kinase, early lytic phase 3783741
Human cytomegalovirus (CMV) RNAs: NC_006273.2
UL83 pp65 Late lytic phase 3077579
UL54 pol CMV DNA polymerase, early lytic phase 3077501
Housekeeper RNAs
CLTC Intracellular trafficking & endocytosis NM_004859.2
GUSB Glucuronidase degrades glycosaminoglycans NM_000181.1
TBP Transcription initiation by TATA box binding protein NM_003194.3
HPRT1 Generation of purine nucleotides NM_000194.1
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Consortium (ERCC number 113, 147 and 163) and then
frozen until RNA expression analysis on the nCounter
system according to manufacturer instructions (Nano-
string). Recovery of the spiked ERCC RNAs served as a
control for integrity of the stored nucleic acid. Further-
more, recovery of 6 different synthetic RNAs built into
the Nanostring reagent system provided confidence that
that Nanostring nCounter analytic test system per-
formed as expected.
The instrument generated a direct digital readout of
the number of each RNA molecule based on
hybridization of patient nucleic acid with multiplexed
pairs of capture and reporter probes tailored to each
RNA of interest, followed by washing away excess
probes, immobilization of biotinylated capture probe-
bound RNAs on a surface, and scanning color-coded bar
tags on each reporter probe. A custom panel of 96 RNA
assays designed for this study included 73 human
mRNAs, 7 latent and 9 lytic EBV mRNA transcripts as
well as EBER1 and EBER2 non-coding RNAs, two cyto-
megalovirus mRNAs, and 3 spiked ERCC RNA controls.
The target human mRNAs were chosen after literature
review to represent the following characteristics, 1) gas-
tric cancer-specific analytes, 2) EBV-dysregulated factors,
3) potential pharmacogenetic biomarkers, 4) inflamma-
tory cell markers, and 4) housekeeping controls. (See
Table 1).
Following analysis, raw expression data was first
adjusted by subtracting the mean counts of 6 negative
controls in the Nanostring reagent system. (Two add-
itional negative controls were omitted because of cross-
reactivity with EBERs.) Negative values were adjusted to
zero, and then data was normalized for 1) technical vari-
ation using the average of 6 positive controls in the
Nanostring reagent system as recommended by the
manufacturer, and 2) endogenous RNA amount or qual-
ity using the average of four housekeeping RNAs
(HPRT1, GUSB, CLTC and TBP). To promote accurateprofiling, only those 182 specimens with the highest
average housekeeping RNA content were used for statis-
tical analysis, while another 140 specimens were
excluded based on low average housekeeping RNA
levels. The cohort of cases for statistical analysis was
comprised of 124 cancers and 58 non-malignant mu-
cosae, while cohort of cases excluded from statistical
analysis because of poor RNA quality was comprised of
80 cancers and 60 non-malignant mucosae. Heat maps
were created to show median-centered expression of
each gene using Cluster 3.0 and JavaTreeView software
algorithms applied to log2 transformed data.
EBV Q-PCR and EBER in situ hybridization
To measure viral DNA load, an aliquot of the same total
nucleic acid extract that had been used for RNA profil-
ing was subjected to quantitative PCR targeting the
BamH1W segment of the EBV genome [94]. A parallel
Q-PCR assay targeting the human APOB gene con-
trolled for efficacy of DNA extraction was used to
normalize for the number of cells represented in the
PCR assay as previously described [94]. Amplification
products were measured on an ABI Prism 7500 Real-
Time PCR instrument using TaqMan probe and Se-
quence Detection System software (Applied Biosystems)
[82], and results reported in copies of EBV DNA per
100,000 cells.
Viral localization to malignant cells was tested using
EBV-encoded RNA (EBER) in situ hybridization on par-
affin sections (BOND assay, Leica Microsystems) [95].
As a quality control, RNA preservation was confirmed
in parallel in situ hybridization to poly A tails by oligo-
dT probe.
Statistics
Unsupervised hierarchical clustering of gastric cancer
tissues revealed the EBV-infected and uninfected mo-
lecular classes of gastric cancer. Three additional tissue
classes (cervical cancer, and benign gastrointestinal or
Tang et al. Infectious Agents and Cancer 2012, 7:21 Page 13 of 15
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teria. In box plots, the median and middle two quartiles
are surrounded by whiskers depicting outliers which are
far above or below the interquartile range (IQR) by >
Q3+ 1.5*IQR or <Q1-1.5*IQR, respectively. Genes sig-
nificantly differentially expressed among groups were
identified using non parametric Mann-Whitney tests
and the p-values were adjusted using the Bonferroni cor-
rection to account for multiple comparisons. A given
RNA was classified as significantly differentially
expressed if its Bonferroni adjusted p value was <0.05
and it was more differentially expressed than any single
one of the four housekeeping RNAs.
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